BPMC Logo

Blueprint Medicines Corporation (BPMC) 

NASDAQ
Market Cap
$6.08B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
582 of 966
Rank in Industry
316 of 554

Largest Insider Buys in Sector

BPMC Stock Price History Chart

BPMC Stock Performance

About Blueprint Medicines Corporation

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Insider Activity of Blueprint Medicines Corporation

Over the last 12 months, insiders at Blueprint Medicines Corporation have bought $0 and sold $39.48M worth of Blueprint Medicines Corporation stock.

On average, over the past 5 years, insiders at Blueprint Medicines Corporation have bought $349,105 and sold $21.15M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,100 shares for transaction amount of $48,378 was made by Haviland Kate (CHIEF EXECUTIVE OFFICER) on 2022‑11‑03.

List of Insider Buy and Sell Transactions, Blueprint Medicines Corporation

2024-11-29SaleCHIEF EXECUTIVE OFFICER
2,353
0.0037%
$96.60$227,304+0.15%
2024-11-27SaleCHIEF OPERATING OFFICER
2,274
0.0036%
$95.10$216,257+1.42%
2024-11-21Saledirector
9,824
0.0151%
$94.87$932,003-1.12%
2024-11-20Saledirector
10,000
0.0157%
$93.77$937,655+1.22%
2024-11-07Saledirector
5,000
0.0079%
$102.00$510,000-4.94%
2024-10-03SalePRESIDENT, R & D
3,633
0.0058%
$89.32$324,500+5.46%
2024-09-09Saledirector
19,702
0.0308%
$85.57$1.69M+4.43%
2024-08-15SaleCHIEF FINANCIAL OFFICER
4,409
0.0071%
$95.23$419,8690.00%
2024-08-05SaleCHIEF COMMERCIAL OFFICER
41,913
0.0663%
$93.19$3.91M-0.84%
2024-07-05SaleCHIEF PEOPLE OFFICER
3,850
0.0066%
$111.20$428,1200.00%
2024-07-03SaleCHIEF PEOPLE OFFICER
8,817
0.0151%
$111.29$981,2440.00%
2024-06-28SaleCHIEF PEOPLE OFFICER
333
0.0006%
$111.15$37,0130.00%
2024-06-21SaleCHIEF PEOPLE OFFICER
74,034
0.1169%
$104.19$7.71M-10.72%
2024-06-05SaleCHIEF SCIENTIFIC OFFICER
4,000
0.0063%
$105.13$420,520-11.28%
2024-06-04SaleCHIEF MEDICAL OFFICER
2,424
0.004%
$104.91$254,302-7.86%
2024-06-03SaleCHIEF SCIENTIFIC OFFICER
2,436
0.0039%
$106.43$259,263-10.52%
2024-06-03SaleCHIEF MEDICAL OFFICER
4,922
0.008%
$106.43$523,848-10.52%
2024-05-31SaleCHIEF MEDICAL OFFICER
34,108
0.0547%
$105.91$3.61M-10.93%
2024-05-15SaleCHIEF FINANCIAL OFFICER
3,850
0.0062%
$106.95$411,772-10.93%
2024-05-15SalePRINCIPAL ACCOUNTING OFFICER
5,856
0.0094%
$106.96$626,379-10.93%

Insider Historical Profitability

2.65%
Albers Jeffrey W.director
157557
0.248%
$95.66055
Haviland KateCHIEF EXECUTIVE OFFICER
150824
0.2374%
$95.66127+10.84%
Rossi ChristinaCHIEF OPERATING OFFICER
71657
0.1128%
$95.6609
Namouni FouadPRESIDENT, R & D
69070
0.1087%
$95.6607
Landsittel MichaelCHIEF FINANCIAL OFFICER
67208
0.1058%
$95.66010
McCain Tracey LEVP AND CHIEF LEGAL OFFICER
60498
0.0952%
$95.6609
Durso-Bumpus DebraCHIEF PEOPLE OFFICER
43763
0.0689%
$95.66015
Carter Percy H.CHIEF SCIENTIFIC OFFICER
41895
0.0659%
$95.6606
Lee PhilinaCHIEF COMMERCIAL OFFICER
34729
0.0547%
$95.6604
Murray Christopher K.CHIEF TECHNICAL OPERATIONS
33853
0.0533%
$95.66011
Hewes L. BeckerCHIEF MEDICAL OFFICER
29514
0.0465%
$95.66014
Hurley ArielPRINCIPAL ACCOUNTING OFFICER
14913
0.0235%
$95.66038
COATS LONNELdirector
2242
0.0035%
$95.6603
Third Rock Ventures II, L.P.10 percent owner
4453753
7.0109%
$95.6601
FMR LLC
264898
0.417%
$95.6619+9.46%
LYNCH DANIELdirector
174342
0.2744%
$95.66010
LEVIN MARK J10 percent owner
111244
0.1751%
$95.6601
Borisy Alexisdirector
60906
0.0959%
$95.6607
Lengauer ChristophChief Scientific Officer
56657
0.0892%
$95.6608
Lydon Nicholasdirector
37425
0.0589%
$95.66011
Boral Anthony L.Chief Medical Officer
28147
0.0443%
$95.66011
Dorsch MarionChief Scientific Officer
15250
0.024%
$95.66014
Goldberg Mark Alan
10812
0.017%
$95.6616<0.0001%
Demetri George
5822
0.0092%
$95.6619<0.0001%
Rowland Charles A Jrdirector
3562
0.0056%
$95.6604
STARR KEVIN P10 percent owner
0
0%
$95.6601

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$611.61M10.36.45M-2.08%-$12.97M0.01
The Vanguard Group$598.56M10.086.31M+3.19%+$18.5M0.01
T. Rowe Price$592.95M9.986.25M+15.14%+$77.96M0.07
Fidelity Investments$490.38M8.265.17M+18.89%+$77.9M0.03
Wellington Management Company$396.05M6.674.18M-2.37%-$9.6M0.07
ROCK SPRINGS CAPITAL MANAGEMENT, LP$237M3.992.5M-13.3%-$36.34M6.17
State Street$208M3.52.19M-9.55%-$21.96M0.01
William Blair Investment Management$162.03M2.731.71M-1.15%-$1.88M0.42
Geode Capital Management$130.08M2.191.37M+3.31%+$4.16M0.01
Lord Abbett$125.06M2.111.32M-9.04%-$12.43M0.44
Macquarie Group$124.38M2.091.31M-16.43%-$24.45M0.11
JPMorgan Chase$124.4M2.091.31M-13.71%-$19.76M0.01
AllianceBernstein$114.17M1.921.2M-11.37%-$14.65M0.04
Morgan Stanley$100.43M1.691.06M-9.35%-$10.36M0.01
T Rowe Price Investment Management Inc$95.16M1.61M-37.25%-$56.5M0.06
Polar Capital$82.05M1.38865,0000%+$00.45
Woodline Partners LP$78.47M1.32827,173+1.56%+$1.2M0.67
Invesco$76.8M1.29809,600+93.88%+$37.19M0.02
Alkeon Capital Management Llc$75.31M1.27793,928+23.3%+$14.23M0.42
American Century Investments$73.05M1.23770,133+8.21%+$5.54M0.05
Holocene Advisors, LP$67.85M1.14715,303New+$67.85M0.25
Brown Advisory$63.97M1.08674,362-0.82%-$527,232.030.09
Goldman Sachs$53.75M0.91566,654-1.97%-$1.08M0.01
Northern Trust$53.02M0.89558,890-2.55%-$1.39M0.01
Charles Schwab$47.54M0.8501,135+5.27%+$2.38M0.01
Hood River Capital Management LLC$44.6M0.75470,126+6.84%+$2.86M1
Avidity Partners Management Lp$40.41M0.68426,000-30.73%-$17.93M1.54
Man Group Plc$38.79M0.65408,880+8.15%+$2.92M0.1
Emerald Advisers, Inc.$38.22M0.64402,910-13.62%-$6.03M1.55
Td Asset Management Inc$36.38M0.61383,470+29.59%+$8.31M0.03
D. E. Shaw & Co.$35.68M0.6376,177+7.69%+$2.55M0.03
Novo Holdings A/S$34.02M0.57358,626-0.14%-$47,430.002.38
Bank of America$31.85M0.54335,775+7.89%+$2.33M<0.01
Fisher Asset Management Llc$31.79M0.54335,128+2.59%+$802,895.010.02
Casdin Capital$30.96M0.52326,3780%+$01.53
Ensign Peak Advisors Inc$30.31M0.51319,528+41.93%+$8.96M0.05
EMERALD MUTUAL FUND ADVISERS TRUST$29.96M0.5315,819-16.95%-$6.11M1.57
Point72 Asset Management$26.54M0.45279,768+591.9%+$22.7M0.04
Nuveen$25.27M0.43266,347-0.15%-$38,987.460.01
Panagora$24.99M0.42263,474-2.6%-$667,434.970.13
BNY Mellon$22.88M0.39241,190-7.43%-$1.84M<0.01
Ubs Asset Management Americas Inc$22.26M0.38234,615-1.91%-$432,371.900.01
Eventide Asset Management$21.98M0.37231,685-25.83%-$7.65M0.36
Marshall Wace$21.85M0.37230,292New+$21.85M0.02
HERITAGE ASSET MANAGEMENT INC$21.33M0.35221,251-4.38%-$978,180.880.11
Voloridge Investment Management, LLC$20.72M0.35218,436+54.93%+$7.35M0.08
Integral Health Asset Management Llc$19.92M0.34210,000+50%+$6.64M2
Victory Capital Management Inc$19.56M0.33206,199+57.34%+$7.13M0.02
The Manufacturers Life Insurance Company$17.48M0.29184,220+35.49%+$4.58M0.02
Spyglass Capital Management LLC$17.28M0.29182,151-28.52%-$6.89M12.95
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.